The IPO Market Is Roaring Back in 2026 — and the Biggest Deals May Still Be Ahead

The initial public offering market has shifted decisively from drought to boom over the past eight months, and the recovery shows little sign of slowing. Medical supply giant Medline's Nasdaq debut in December 2025 became the largest private-equity-backed IPO in history, raising $6.26 billion in an upsized offering priced at $29 a share. The stock opened at $35 and closed its first session up more than 41% at $41, valuing the company at roughly $46 billion at the open — the largest US IPO since Rivian's 2021 listing.

A market that had been dormant since 2021

Medline's listing capped what was already the best year for new issues since the 2021 boom, following successful debuts earlier in the cycle from crypto-trading platform Circle, fintech firm Klarna, and cloud-computing company CoreWeave. Those three deals had already begun rebuilding investor confidence in new listings after a multi-year IPO drought driven by rate volatility and depressed growth-stock valuations. Medline's performance — and its durability since, with shares still trading well above their offer price into mid-2026 — has functioned as proof of concept that public markets retain a genuine appetite for high-quality, profitable private companies, not just speculative growth names.

Private equity firms have particularly welcomed the reopening. Blackstone, Carlyle Group and Hellman & Friedman acquired a majority stake in Medline for $34 billion in 2021, one of the largest leveraged buyouts on record; a successful public exit gives the industry a template for unlocking value from a backlog of aging buyout-era holdings that have been waiting on the sidelines for a receptive IPO window.

What's reportedly coming next

The pipeline behind Medline is where the story gets more interesting for markets broadly. SpaceX has reportedly moved toward a public listing after facilitating an insider share sale that valued Elon Musk's rocketry and satellite business at roughly $800 billion — a scale that, if it proceeds to a full IPO, would dwarf every listing of the past decade. Database company Databricks, which raised private funding at a $134 billion valuation, has signaled it could explore a public offering as soon as next year. And major AI labs including OpenAI and Anthropic are reportedly exploring public listings within the next 18 months, according to reporting from The Information — a development that would bring some of the most closely watched private companies in technology into public markets for the first time.

Reading the signals for retail and institutional investors

For investors, an accelerating IPO calendar typically signals two things simultaneously: rising confidence among underwriters and institutional buyers that current valuations can hold up under public-market scrutiny, and a growing incentive for late-stage private companies to lock in liquidity while the window stays open. Medline's post-IPO trajectory — a 52-week high near $50.88 before consolidating into the high-$30s range by mid-2026 — is also a useful reminder that even well-received debuts rarely move in a straight line, and that first-day pops do not guarantee sustained outperformance.

What to watch through year-end

With medtech, AI infrastructure and enterprise software all represented in the current and prospective IPO pipeline, 2026 is shaping up as a genuine test of how deep investor demand for new issues actually runs. If a handful of the megadeals reportedly in the pipeline — particularly SpaceX and Databricks — do materialize before year-end, 2026 could surpass 2021 as the strongest year for IPO proceeds in market history. Investors tracking the space should watch upcoming S-1 filings closely, since the sequencing and pricing of these mega-listings will heavily influence sentiment across the broader growth and technology-stock complex into 2027.